Viridian Therapeutics, Inc.\DE (VRDN) Gross Margin (2013 - 2016)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Gross Margin of 35.95% for Q4 2016, down 6676.0% year-over-year from 0.55% in Q1 2016, and down 199.86% quarter-over-quarter from 36.0% in Q3 2016.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Gross Margin (2013 - 2016) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Gross Margin history runs 4 years deep, the most recent figure standing at 35.95% for Q4 2016.
- In Q4 2016, Gross Margin fell 6676.0% year-over-year to 35.95%; the TTM figure through Dec 2016 stood at 26.72% (down 2.0% YoY), while the FY2016 annual figure was 284.31%, down 28691.0% from the prior year.
- Gross Margin for Q4 2016 stood at 35.95%, down from 36.0% in the prior quarter.
- The five-year high for Gross Margin was 56.78% in Q3 2015, with the low at 35.95% in Q4 2016.
- The 4-year median for Gross Margin is 34.5% (2014), against an average of 25.79%.
- The sharpest annual moves came in 2015 and 2016: Gross Margin soared 5004 bps in 2015, then tumbled 6676 bps in 2016.
- Viridian Therapeutics, Inc.\DE's Gross Margin stood at 50.35% in 2013, then slumped by 138 bps to 19.24% in 2014, then soared by 260 bps to 30.8% in 2015, then sank by 217 bps to 35.95% in 2016.
- Business Quant data shows VRDN's Gross Margin at 35.95% in Q4 2016, 36.0% in Q3 2016, and 43.68% in Q2 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2016 | -35.95% |
| Sep 30, 2016 | 36.00% |
| Jun 30, 2016 | 43.68% |
| Mar 31, 2016 | 31.41% |
| Dec 31, 2015 | 71.80% |
| Sep 30, 2015 | 56.78% |
| Jun 30, 2015 | 53.47% |
| Mar 31, 2015 | 42.29% |
| Dec 31, 2014 | 48.18% |
| Sep 30, 2014 | 51.92% |
| Jun 30, 2014 | 41.15% |
| Mar 31, 2014 | 50.74% |
| Sep 30, 2013 | 50.35% |
| Jun 30, 2013 | 51.33% |